392 related articles for article (PubMed ID: 26275522)
21. Repetitive infusion of levosimendan in patients with chronic heart failure: a meta-analysis.
Yi GY; Li JX; Zhang J; Niu LL; Zhang CY
Med Sci Monit; 2015 Mar; 21():895-901. PubMed ID: 25811545
[TBL] [Abstract][Full Text] [Related]
22. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
23. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
24. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis.
Harrison RW; Hasselblad V; Mehta RH; Levin R; Harrington RA; Alexander JH
J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1224-32. PubMed ID: 24050857
[TBL] [Abstract][Full Text] [Related]
25. Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials.
Bhattacharjee S; Soni KD; Maitra S; Baidya DK
J Clin Anesth; 2017 Jun; 39():67-72. PubMed ID: 28494911
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis.
Qiu J; Jia L; Hao Y; Huang S; Ma Y; Li X; Wang M; Mao Y
Life Sci; 2017 Sep; 184():30-36. PubMed ID: 28689804
[TBL] [Abstract][Full Text] [Related]
27. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis.
Koster G; Wetterslev J; Gluud C; Zijlstra JG; Scheeren TW; van der Horst IC; Keus F
Intensive Care Med; 2015 Feb; 41(2):203-21. PubMed ID: 25518953
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
García González MJ; Domínguez Rodríguez A
Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
[TBL] [Abstract][Full Text] [Related]
30. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis.
Silvetti S; Nieminen MS
Int J Cardiol; 2016 Jan; 202():138-43. PubMed ID: 26386941
[TBL] [Abstract][Full Text] [Related]
31. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
32. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
Nieminen MS; Sandell EP
Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369
[TBL] [Abstract][Full Text] [Related]
33. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
34. Is there a place for levosimendan in the intensive care unit?
Delaney A; Bradford C; McCaffrey J; Bagshaw SM; Lee R
Crit Care Resusc; 2007 Sep; 9(3):290-2. PubMed ID: 17767458
[TBL] [Abstract][Full Text] [Related]
35. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
Lehtonen L
Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
[TBL] [Abstract][Full Text] [Related]
36. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.
Silvetti S; Greco T; Di Prima AL; Mucchetti M; de Lurdes CM; Pasin L; Scandroglio M; Landoni G; Zangrillo A
Clin Res Cardiol; 2014 Jul; 103(7):505-13. PubMed ID: 24368740
[TBL] [Abstract][Full Text] [Related]
37. [Hemodynamic and efficacies of domestic levosimendan versus dobutamine in patients with acute decompensated heart failure].
Zhang YH; Qing EM; Zhang J; Huang Y; Lü R; Zhou Q; Wei BQ; An T; Qing P; Zou CH
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):555-8. PubMed ID: 22490161
[TBL] [Abstract][Full Text] [Related]
38. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.
Packer M; Colucci W; Fisher L; Massie BM; Teerlink JR; Young J; Padley RJ; Thakkar R; Delgado-Herrera L; Salon J; Garratt C; Huang B; Sarapohja T;
JACC Heart Fail; 2013 Apr; 1(2):103-11. PubMed ID: 24621834
[TBL] [Abstract][Full Text] [Related]
39. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
[TBL] [Abstract][Full Text] [Related]
40. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
